Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Extra Corpor Technol ; 54(4): 338-342, 2022 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-36742021

RESUMEN

Alagille syndrome is an autosomal dominant disorder that is caused by heterozygous mutation of JAG1 or NOTCH2 gene that impacts several multisystem organs including but may not be limited to the liver, heart, musculoskeletal, skin, and the eyes. The most common congenital heart defect associated with Alagille syndrome is multilevel right ventricular outflow tract obstruction with multiple central and peripheral branch pulmonary arterial stenoses occurring in up to two-thirds of these patients. We report two cases of Alagille syndrome who underwent extensive pulmonary arterial branch rehabilitation and experienced unusual oxygenator failure during cardiopulmonary bypass (CPB). We present lessons learned from these two cases and the changes that we implemented in our practice that facilitated smooth conduct of CPB in other cases that we performed subsequently.


Asunto(s)
Síndrome de Alagille , Cardiopatías Congénitas , Hipertensión Pulmonar , Humanos , Síndrome de Alagille/complicaciones , Síndrome de Alagille/cirugía , Síndrome de Alagille/genética , Puente Cardiopulmonar/efectos adversos , Hipertensión Pulmonar/complicaciones , Oxigenadores/efectos adversos
2.
Pediatr Allergy Immunol ; 25(2): 180-6, 2014 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24520985

RESUMEN

BACKGROUND: Infants born prematurely are often treated with supplemental oxygen, which can increase their risk for airway hyper-responsiveness (AHR), asthma, reduced lung function, and altered responses to respiratory viral infections later in childhood. Likewise, exposure of newborn mice to hyperoxia alters baseline pulmonary mechanics and the host response to influenza A virus infection in adult mice. Here, we use this mouse model to test the hypothesis that neonatal hyperoxia also promotes AHR and exacerbated allergen-induced symptoms in adult mice. METHODS: Baseline lung mechanics and AHR measured by methacholine provocation were assessed in adult male and female mice exposed to room air or 100% oxygen (hyperoxia) between post-natal days 0-4. AHR and lung inflammation were evaluated after adult female mice were sensitized with ovalbumin (OVA) plus alum and challenged with aerosolized OVA. RESULTS: Baseline lung compliance increased and resistance decreased in adult female, but not male, mice exposed to neonatal hyperoxia compared with siblings exposed to room air. Neonatal hyperoxia significantly enhanced methacholine-induced AHR in female mice, but did not affect allergen-induced AHR to methacholine or lung inflammation. CONCLUSION: Increased incidence of AHR and asthma is reported in children born prematurely and exposed to supplemental oxygen. Our findings in adult female mice exposed to hyperoxia as neonates suggest that this AHR reported in children born prematurely may reflect non-atopic wheezing due to intrinsic structural changes in airway development.


Asunto(s)
Hiperreactividad Bronquial/fisiopatología , Broncoconstricción , Hiperoxia/fisiopatología , Pulmón/fisiopatología , Neumonía/fisiopatología , Factores de Edad , Resistencia de las Vías Respiratorias , Animales , Animales Recién Nacidos , Hiperreactividad Bronquial/inducido químicamente , Hiperreactividad Bronquial/diagnóstico , Pruebas de Provocación Bronquial , Broncoconstrictores/farmacología , Modelos Animales de Enfermedad , Femenino , Hiperoxia/complicaciones , Hiperoxia/diagnóstico , Rendimiento Pulmonar , Masculino , Cloruro de Metacolina , Ratones Endogámicos C57BL , Datos de Secuencia Molecular , Ovalbúmina , Neumonía/inducido químicamente , Neumonía/diagnóstico , Factores de Riesgo , Factores Sexuales
3.
Mol Immunol ; 56(1-2): 91-7, 2013 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-23685261

RESUMEN

Preeclampsia is a major obstetric problem defined by new-onset hypertension and proteinuria associated with compromised placental perfusion. Although activation of the complement system is increased in preeclampsia compared to normal pregnancy, it remains unclear whether excess complement activation is a cause or consequence of placental ischemia. Therefore, we hypothesized that complement activation is critical for placental ischemia-induced hypertension. We employed the reduced utero-placental perfusion pressure (RUPP) model of placental ischemia in the rat to induce hypertension in the third trimester and evaluated the effect of inhibiting complement activation with a soluble recombinant form of an endogenous complement regulator, human complement receptor 1 (sCR1; CDX-1135). On day 14 of a 21-day gestation, rats received either RUPP or Sham surgery and 15 mg/kg/day sCR1 or saline intravenously on days 14-18. Circulating complement component 3 decreased and complement activation product C3a increased in RUPP vs. Sham (p<0.05), indicating complement activation had occurred. Mean arterial pressure (MAP) measured on day 19 increased in RUPP vs. Sham rats (109.8±2.8 mmHg vs. 93.6±1.6 mmHg). Treatment with sCR1 significantly reduced elevated MAP in RUPP rats (98.4±3.6 mmHg, p<0.05) and reduced C3a production. Vascular endothelial growth factor (VEGF) decreased in RUPP compared to Sham rats, and the decrease in VEGF was not affected by sCR1 treatment. Thus, these studies have identified a mechanistic link between complement activation and the pregnancy complication of hypertension apart from free plasma VEGF and have identified complement inhibition as a potential treatment strategy for placental ischemia-induced hypertension in preeclampsia.


Asunto(s)
Activación de Complemento/fisiología , Hipertensión/fisiopatología , Isquemia/fisiopatología , Placenta/fisiopatología , Animales , Presión Arterial/efectos de los fármacos , Arterias Carótidas/efectos de los fármacos , Arterias Carótidas/fisiopatología , Activación de Complemento/efectos de los fármacos , Complemento C3/metabolismo , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Hipertensión/sangre , Hipertensión/metabolismo , Técnicas In Vitro , Masculino , Nitroprusiato/farmacología , Placenta/irrigación sanguínea , Placenta/metabolismo , Preeclampsia/sangre , Preeclampsia/metabolismo , Preeclampsia/fisiopatología , Embarazo , Ratas , Ratas Sprague-Dawley , Receptores de Complemento/administración & dosificación , Factores de Tiempo , Útero/irrigación sanguínea , Útero/metabolismo , Útero/fisiopatología , Factor A de Crecimiento Endotelial Vascular/sangre , Factor A de Crecimiento Endotelial Vascular/metabolismo , Receptor 1 de Factores de Crecimiento Endotelial Vascular/sangre , Receptor 1 de Factores de Crecimiento Endotelial Vascular/metabolismo , Vasodilatación/efectos de los fármacos , Vasodilatadores/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA